An Early Phase 1 interventional study of Natesto testosterone intranasal gel and Ayr Saline Nasal Gel in Spinal Cord Injury, sponsored by VA Office of Research and Development. Recruiting at 1 site in United States. Open to male participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by VA Office of Research and Development · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Spinal Cord Injuries by VA Office of Research and Development — 17 open to participants now, 18 under way, 1 of them phase 3. Spinal Cord Injuries · VA Office of Research and Development.
Among the 76 studies in Spinal Cord Injuries by VA Office of Research and Development, this one is the 41st largest by planned enrollment of the 69 interventional ones that give a count, is one of 4 that started in 2024, is one of 3 in phase 1, reaches primary completion later than 1 of the 17 other live ones, and was the 68th registered.
2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.
Browse Spinal Cord Injuries studies →17 of the 76 studies in Spinal Cord Injuries by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 18–60
VA Office of Research and Development · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.
This study: 18 Years to 80 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 13 · Phase 3 6 · Phase 4 1
First in 2003; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 24 across 1,639 interventional studies indexed under Spinal Cord Injuries.
Median enrollment 20 across the 69 interventional studies, 53 across the 7 observational. Of the 57 that completed or were terminated, 50 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
VA Office of Research and Development is the lead sponsor of 1,774 studies on the registry; 394 are open to participants now.
Of its 213 completed or terminated interventional studies of FDA-regulated products, 185 (87%) have results posted.
9 of the studies in Spinal Cord Injuries by VA Office of Research and Development that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05776030VA Office of Research and DevelopmentMulti-speed Ergonomic Wheelchair | 2026-12-31 |
| NCT06130449VA Office of Research and DevelopmentTestosterone and Neural Function in Men With Spinal Cord Injury | 2026-12-31 |
| NCT05157282VA Office of Research and DevelopmentSpinal Cord Stimulation for Functional Recovery in Humans With Tetraplegia | 2027-01-29 |
| NCT05553353VA Office of Research and DevelopmentDosing rTMS for Depression Post-SCI | 2027-04-15 |
| NCT05926596VA Office of Research and DevelopmentLeg Stretching Using an Exoskeleton on Demand for People With Spasticity | 2027-04-30 |
Add all 9 to your calendar (.ics) → With an account.
Among the 76 studies in Spinal Cord Injuries by VA Office of Research and Development, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Spinal cord injury (SCI) disrupts the nerves controlling movement, along with those that regulate functions like heart rate and blood pressure (known as the autonomic nervous system, or ANS). Testosterone (T) plays a significant role in brain health and ANS reflex function in non-neurologically impaired men. However, little is known about the relationships between T, nerve function, and ANS dysfunction after SCI. Interestingly, up to 60% of men with SCI exhibit persistently low T concentrations, which may worsen nerve and ANS dysfunction. In uninjured eugonadal people (normal physiologic range of serum T concentrations), a single pharmacologic dose of intranasal T has been shown to quickly improve nerve function, but no study has evaluated if T administration alters nerve and ANS function in men with SCI. Herein, the investigators will conduct the first study to test how a single dose of intranasal T impacts motor and ANS function in this population.
Spinal cord injury (SCI) disrupts sensorimotor function and corticospinal excitability, resulting in muscle weakness and autonomic nervous system (ANS) dysfunction that detracts from cardiovascular (CV) health. These deficits may be exacerbated by low testosterone (T), which develops in most men during the acute/subacute phases of SCI and persists in 45-60% of men thereafter. Low T (hypogonadism) is associated with multiple health impairments, including reduced lean tissue mass and increased fat mass, systemic inflammation, and risk for CV and neurodegenerative diseases. Moreover, low T is associated with CV ANS dysfunction and impaired cardiovagal (parasympathetic) reflex function following SCI. In men with low T after SCI, restoring T concentrations to the normal (eugonadal) range with T replacement therapy (TRT) improves energy expenditure, body composition, CV function, and markers of cardiometabolic health. Evidence from animal models also demonstrates that T is neuroprotective, upregulates neurotrophic factors, and promotes neuroplasticity and myelin regeneration. However, the neural effects of intranasal TRT are unknown.
T is the most abundant bioactive androgen within the circulation. It exerts direct biological actions by binding androgen receptors (ARs), affecting transcription, as well as non-genomic mechanisms in the brain, spinal cord, heart, and numerous other tissues throughout the body. The majority of circulating T is bound to sex-hormone binding globulin (SHBG) and albumin, with only 1-4% circulating unbound (free T). Free T and albumin-bound T are collectively termed bioavailable T, as SHBG-bound T cannot readily dissociate to engage cellular receptors. In this regard, a high prevalence of men with SCI not only exhibit low total T, but also exhibit a marked reduction in bioavailable T because there is a >10-fold increase in SHBG after SCI, resulting in lower proportions of free and albumin-bound T.
The primary goal of this proposal is to perform a small pilot/feasibility study to assess neurophysiological and cardiovagal responses to a single dose of intranasal TRT in a cohort of these men who exhibit low Total T (\<300 ng/dL), low Free T (\<46 pg/mL), or low bioavailable T (\<110 ng/dL) and hypogonadal signs/symptoms.
Primary Aim: To investigate the acute effects of a single dose of intranasal TRT (11 mg) compared with placebo on CNS excitability and cardiovagal reflex function 30 minutes after administration in 15 male Veterans (10 with chronic SCI and 5 uninjured controls) who have low baseline total T concentrations. CNS excitability will be assessed using hand muscle electromyography (EMG) output determined by recruitment curves evoked by non-invasive single-pulse transcranial magnetic stimulation (TMS) and cervical transcutaneous spinal cord stimulation (TSCS). A cold face challenge (CFC) while measuring beat-to-beat heart rate signals will be used to examine CV ANS reflex function. Because this Exploratory Aim is a pilot/feasibility study, formal hypothesis testing would be premature. However, based on the literature, the investigators expect that elevating circulating concentrations of T into the high normal physiologic range via intranasal TRT will result in improved neural and cardiovagal function for 6-8 hours after the dose.
The results of this pilot study will inform feasibility and identify modifications needed to design a larger eventual trial to evaluate the efficacy and safety of intranasal TRT. Ours will be the first clinical study to collect pilot/feasibility data on an intranasal TRT formulation that has the potential to improve neural function after SCI. This is significant because our results are expected to provide evidence demonstrating the feasibility of a novel intranasal therapeutic strategy in Veterans with SCI.
The criteria were revised on the registry on Oct 6, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participant-blinded (Ayr Saline Gel)
Drug: Ayr Saline Nasal Gel
Participant-blinded (11 mg of Natesto)
Drug: Natesto testosterone intranasal gel
A single dose of Natesto (11 mg total, 5.5 mg per nostril) will be administered to each participant.
Also known as: testosterone intranasal gel
A single dose of Ayr (one spray per nostril) will be administered to each participant.
Also known as: Saline Nasal Gel
Electromyographic (EMG) responses
Response to electrical and magnetic stimulation, singly, will be measured via peak-to-peak amplitude (millivolts) in first dorsal interosseous and abductor pollicis brevis muscles.
Time frame: up to one day
Serum Testosterone
Serum testosterone will be assessed prior to and after administration of intranasal TRT.
Time frame: up to one day
Cardiovagal Function (heart rate variability)
Changes in beat-by-beat heart rate (beats per minute) signals collected using ECG during a cold face challenge (cardiovagal provocation) to determine cardiovagal reflex function. Changes in the high frequency (0.15-0.4 Hz) component will be used as an indication of parasympathetic activity to the heart.
Time frame: up to one day
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2024 (actual). Primary completion is estimated for Dec 2026, 32 months after the start.
Of 40 non-industry phase 1 interventional studies under Spinal Cord Injuries, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 55. This study's planned 32 months is below that.
Counting every sponsor, half of 51 studies reached it within 36 months; a quarter within 24 and three quarters within 55.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Sep 2026 → Dec 2026 and completion Sep 2026 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
VA Office of Research and Development →